Search

Artificial intelligence (AI) has been widely applied in drug discovery with a major task as molecular property prediction. Despite booming techniques in molecular representation learning, key elements underlying molecular property prediction remain largely unexplored, which impedes further advancements in this field. Herein, we conduct an extensive evaluation of representative models using various representations on the MoleculeNet datasets, a suite of opioids-related datasets and two additional activity datasets from the literature. To investigate the predictive power in low-data and high-data space, a series of descriptors datasets of varying sizes are also assembled to evaluate the models. In total, we have trained 62,820 models, including 50,220 models on fixed representations, 4,200 models on SMILES sequences and 8,400 models on molecular graphs. Based on extensive experimentation and rigorous comparison, we show that representation learning models exhibit limited performance in molecular property prediction in most datasets. Besides, multiple key elements underlying molecular property prediction can affect the evaluation results. Furthermore, we show that activity cliffs can significantly impact model prediction. Finally, we explore into potential causes why representation learning models can fail and show that dataset size is essential for representation learning models to excel.

Artificial intelligence (AI) has been transforming the practice of drug discovery in the past decade. Various AI techniques have been used in a wide range of applications, such as virtual screening and drug design. In this survey, we first give an overview on drug discovery and discuss related applications, which can be reduced to two major tasks, i.e., molecular property prediction and molecule generation. We then discuss common data resources, molecule representations and benchmark platforms. Furthermore, to summarize the progress of AI in drug discovery, we present the relevant AI techniques including model architectures and learning paradigms in the papers surveyed. We expect that this survey will serve as a guide for researchers who are interested in working at the interface of artificial intelligence and drug discovery. We also provide a GitHub repository (https://github.com/dengjianyuan/Survey_AI_Drug_Discovery) with the collection of papers and codes, if applicable, as a learning resource, which is regularly updated., Comment: Accepted to Briefings in Bioinformatics

The United States is experiencing an opioid epidemic, and there were more than 10 million opioid misusers aged 12 or older each year. Identifying patients at high risk of Opioid Use Disorder (OUD) can help to make early clinical interventions to reduce the risk of OUD. Our goal is to predict OUD patients among opioid prescription users through analyzing electronic health records with machine learning and deep learning methods. This will help us to better understand the diagnoses of OUD, providing new insights on opioid epidemic. Electronic health records of patients who have been prescribed with medications containing active opioid ingredients were extracted from Cerner Health Facts database between January 1, 2008 and December 31, 2017. Long Short-Term Memory (LSTM) models were applied to predict opioid use disorder risk in the future based on recent five encounters, and compared to Logistic Regression, Random Forest, Decision Tree and Dense Neural Network. Prediction performance was assessed using F-1 score, precision, recall, and AUROC. Our temporal deep learning model provided promising prediction results which outperformed other methods, with a F1 score of 0.8023 and AUCROC of 0.9369. The model can identify OUD related medications and vital signs as important features for the prediction. LSTM based temporal deep learning model is effective on predicting opioid use disorder using a patient past history of electronic health records, with minimal domain knowledge. It has potential to improve clinical decision support for early intervention and prevention to combat the opioid epidemic., Comment: 20 pages, 6 figures

Naloxone, an opioid antagonist, has been widely used to save lives from opioid overdose, a leading cause for death in the opioid epidemic. However, naloxone has short brain retention ability, which limits its therapeutic efficacy. Developing better opioid antagonists is critical in combating the opioid epidemic.Instead of exhaustively searching in a huge chemical space for better opioid antagonists, we adopt reinforcement learning which allows efficient gradient-based search towards molecules with desired physicochemical and/or biological properties. Specifically, we implement a deep reinforcement learning framework to discover potential lead compounds as better opioid antagonists with enhanced brain retention ability. A customized multi-objective reward function is designed to bias the generation towards molecules with both sufficient opioid antagonistic effect and enhanced brain retention ability. Thorough evaluation demonstrates that with this framework, we are able to identify valid, novel and feasible molecules with multiple desired properties, which has high potential in drug discovery., Comment: 10 pages, 7 figures

Drug-drug interactions (DDI) can cause severe adverse drug reactions and pose a major challenge to medication therapy. Recently, informatics-based approaches are emerging for DDI studies. In this paper, we aim to identify key pharmacological components in DDI based on large-scale data from DrugBank, a comprehensive DDI database. With pharmacological components as features, logistic regression is used to perform DDI classification with a focus on searching for most predictive features, a process of identifying key pharmacological components. Using univariate feature selection with chi-squared statistic as the ranking criteria, our study reveals that top 10% features can achieve comparable classification performance compared to that using all features. The top 10% features are identified to be key pharmacological components. Furthermore, their importance is quantified by feature coefficients in the classifier, which measures the DDI potential and provides a novel perspective to evaluate pharmacological components., Comment: Accepted to AMIA 2020 Informatics Summit

The use of color in QR codes brings extra data capacity, but also inflicts tremendous challenges on the decoding process due to chromatic distortion, cross-channel color interference and illumination variation. Particularly, we further discover a new type of chromatic distortion in high-density color QR codes, cross-module color interference, caused by the high density which also makes the geometric distortion correction more challenging. To address these problems, we propose two approaches, namely, LSVM-CMI and QDA-CMI, which jointly model these different types of chromatic distortion. Extended from SVM and QDA, respectively, both LSVM-CMI and QDA-CMI optimize over a particular objective function to learn a color classifier. Furthermore, a robust geometric transformation method and several pipeline refinements are proposed to boost the decoding performance for mobile applications. We put forth and implement a framework for high-capacity color QR codes equipped with our methods, called HiQ. To evaluate the performance of HiQ, we collect a challenging large-scale color QR code dataset, CUHK-CQRC, which consists of 5390 high-density color QR code samples. The comparison with the baseline method [2] on CUHK-CQRC shows that HiQ at least outperforms [2] by 188% in decoding success rate and 60% in bit error rate. Our implementation of HiQ in iOS and Android also demonstrates the effectiveness of our framework in real-world applications., Comment: 15 pages, 10 figures, submitted to IEEE Transaction on Image Processing